Dr. Rodger Novak, MD, Founded CRISPR Therapeutics AG in November 2013 and serves as its Chief Executive Officer. Dr. Novak served as the Chief Operating Officer and Managing Director of Nabriva Therapeutics AG (formerly Nabriva Therapeutics Forschungs GmbH) since January 2006. He was a Co-founder of Nabriva Therapeutics AG. He is an experienced pharmaceutical and biotechnology executive with more than 15 years experience in clinical, academic and pharmaceutical infectious diseases gained in Germany, USA and Austria. He was global head anti-infectives R&D at Sanofi, where he was responsible for small molecule and biologics R&D, including early drug discovery and clinical development. He has been a Director of CRISPR Therapeutics AG since October 2013. He served as a Associate Professor at the University of Vienna since 2001. As Head of Scientific and Medical Affairs and Deputy Head of the Antibiotic Research Institute (ABRI), a unit of Sandoz GmbH, he built-up the development organization directing 40 research and development staff at the Vienna site. During his academic career he authored numerous publications, among them articles in Nature, Nature Medicine and Molecular Cell. He was a postdoctoral fellow at The Rockefeller University, St Jude Children’s Research Hospital and the Skirball Institute NYU Medical Center. Dr. Novak received his MD from the Philipps University in Marburg, Germany in 1993 and his foreign medical license for the US in 1994.

 Pharmaceutical Sciences